Armata Pharmaceuticals
AP-SA02, an IV phage cocktail dosed alongside standard antibiotics for complicated S. aureus bacteremia, read out positive Phase 2a data in May 2025, received FDA Qualified Infectious Disease Product designation,…
- Country
- United States
- Ticker
- ARMP
Clinical
Coverage
| CN | EU | US | |
|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Bacteriophage therapy | therapeutics-platforms | High | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.